Use of ivermectin in the treatment of Covid-19: A pilot trial.

ABSTRACT:

Objectives

In this randomized open-label trial pilot study we assessed the antiviral effects and safety of various doses of ivermectin in patients with mild clinical symptoms of COVID-19.

Methods

Patients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS-CoV-2 RT PCR tests within 7 days of the start of the dosing period. This study was registered at ClinicalTrials.gov (NCT04431466).

Results

A total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious advers

SUBMITTER: Pott-Junior H 

PROVIDER: S-EPMC7942165 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature